Docosahexaenoic acid and non-alcoholic fatty liver disease in obese children: a novel approach?

Journal of Translational Medicine

Laura Soldati¹  Giovanni Radaelli¹  Carlotta Lassandro¹  Elvira Verduci¹ 

[1] Department of Health Sciences, University of Milan, Milan, Italy

关键词: n-3 LCPUFA;    NAFLD;    Childhood obesity;    DHA;   

Others  :  1207767
DOI  :  10.1186/s12967-015-0471-7

 received in 2015-03-16, accepted in 2015-03-20,  发布年份 2015

【 摘 要 】

Non-alcoholic fatty liver disease represents the most common chronic liver disease in obese children of industrialized countries. Nowadays the first line of treatment of pediatric non-alcoholic fatty liver disease is based on dietary and lifestyle intervention; however compliance to these interventions is very difficult to maintain in long term period. This editorial discusses about docosahexaenoic acid treatment as possible novel approach for non-alcoholic fatty liver disease in obese children. Docosahexaenoic acid may modulate the inflammatory response, improve insulin sensitivity and could be effective in enhancing intestinal barrier integrity, essential to protect a healthy gut-liver axis. Indeed alteration of gut microbiota composition and increased intestinal permeability may rise the exposure of liver to gut-derived bacterial products, causing activation of signalling pathways implicated in liver inflammation and fibrogenesis. This mechanism has been observed in vitro and animal models of non-alcoholic fatty liver disease but also in a clinical study in adults. While evidence suggests that n-3 long-chain polyunsaturated fatty acids supplementation may decrease liver fat in adults, in pediatric population only a study examined this topic. In obese children with non-alcoholic fatty liver disease well designed randomized controlled trials are needed to better clarify the possible efficacy of docosahexaenoic acid treatment, and underlying mechanisms, to identify the optimal required dose and to evaluate if the docosahexaenoic acid effect is limited to the duration of the treatment or it may continue after the end of treatment.

【 授权许可】

   
2015 Verduci et al.; licensee BioMed Central.

【 参考文献 】

• [1]Nobili V, Alkhouri N, Alisi A, Della Corte C, Fitzpatrick E, Raponi M et al.. Nonalcoholic Fatty Liver Disease: A Challenge for Pediatricians. JAMA Pediatr. 2015; 169:170-6.
• [2]Paolella G, Mandato C, Pierri L, Poeta M, Di Stasi M, Vajro P. Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease. World J Gastroenterol. 2014; 20:15518-31.
• [3]Giorgio V, Miele L, Principessa L, Ferretti F, Villa MP, Negro V et al.. Intestinal permeability is increased in children with non-alcoholic fatty liver disease, and correlates with liver disease severity. Dig Liver Dis. 2014; 46:556-60.
• [4]Miele L, Valenza V, La Torre G, Montalto M, Cammarota G, Ricci R et al.. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology. 2009; 49:1877-87.
• [5]Masterton GS, Plevris JN, Hayes PC. Review article: omega-3 fatty acids - a promising novel therapy for non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2010; 31:679-92.
• [6]Parker HM, Johnson NA, Burdon CA, Cohn JS, O’Connor HT, George J. Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol. 2012; 56:944-51.
• [7]Nobili V, Alisi A, Della Corte C, Risé P, Galli C, Agostoni C et al.. Docosahexaenoic acid for the treatment of fatty liver: randomised controlled trial in children. Nutr Metab Cardiovasc Dis. 2013; 23:1066-70.
• [8]Pozzato C, Radaelli G, Dall’Asta C, Verduci E, Villa A, Villa C et al.. MRI in identifying hepatic steatosis in obese children and relation to ultrasonography and metabolic findings. J Pediatr Gastroenterol Nutr. 2008; 47:493-9.
• [9]Fishbein M, Castro F, Cheruku S, Jain S, Webb B, Gleason T et al.. Hepatic MRI for fat quantification: its relationship to fat morphology, diagnosis, and ultrasound. J Clin Gastroenterol. 2005; 39:619-25.
• [10]Nobili V, Bedogni G, Alisi A, Pietrobattista A, Alterio A, Tiribelli C et al.. A protective effect of breastfeeding on the progression of non-alcoholic fatty liver disease. Arch Dis Child. 2009; 94:801-5.
• [11]Verduci E, Banderali G, Barberi S, Radaelli G, Lops A, Betti F et al.. Epigenetic effects of human breast milk. Nutrients. 2014; 6:1711-24.
• [12]Tabbaa M, Golubic M, Roizen MF, Bernstein AM. Docosahexaenoic acid, inflammation, and bacterial dysbiosis in relation to periodontal disease, inflammatory bowel disease, and the metabolic syndrome. Nutrients. 2013; 5:3299-310.